Vlad CoricNEW HAVEN: Vlad Coric CEO of Biohaven Pharmaceutical Holding Company Ltd. [NYSE:BHVN], based in downtown New Haven has been by Ernst & Young as its Entrepreneur Of The Year 2018 Award Winner in New York Region for the Health Care Category.

EY’s awards program “recognizes entrepreneurs who are excelling in areas such as innovation, financial performance and personal commitment to their businesses and communities. Dr. Coric was selected as an award winner by a panel of independent judges.”

With the regional award Coric is eligible for the national competition, announced in November.

Biohaven is a clinical-stage biopharmaceutical company with a portfolio of, late-stage product candidates targeting neurological diseases, including rare disorders. The company first went public in May of 2017 at just under $18 per share. The stock has risen to $39.40 [June 15, 2018]and $1.56 billion market value.

Biohaven near instant pipeline of drugs has built through a combination of internal development and research with intellectual property licensed from companies and institutions including Bristol-Myers Squibb Company, AstraZeneca AB, Yale University, Catalent, Rutgers, ALS Biopharma LLC and Massachusetts General Hospital.

Biohaven leading’s clinical effort is with the licensed drug Rimegepant, for the acute treatment of migraine.